Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.60 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013746 | 0.81 | MKNK1 (0.53) | PDE10AKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL3233745 | 0.75 | KCNN3 (1.00) | KCNN2KCNN3KMT2ALMNAMEN1 | |
| SCHEMBL29355074 | 0.75 | KCNN3 (1.00) | KCNN2KCNN3KMT2ALMNAMEN1 | |
| SCHEMBL4017740 | 0.74 | CCR4 (0.57) | KMT2AMEN1SMN1; SMN2PDE10AKDM4E | |
| SCHEMBL4207857 | 0.74 | KCNN3 (0.97) | KCNN2KCNN3LMNASMN1; SMN2HTT | |
| SCHEMBL27253441 | 0.73 | MAPK10 (0.46) | LMNAPDE10AKDM4EGAANPC1 | |
| SCHEMBL4014605 | 0.73 | NPC1 (0.50) | KCNN3KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL14193418 | 0.69 | MAPK8 (0.79) | MAPK10MAPK8MAPK9 | |
| SCHEMBL2019571 | 0.69 | LMNA (0.61) | KCNN2KCNN3KMT2ALMNAMEN1 | |
| SCHEMBL14233966 | 0.67 | NUDT1 (0.71) | KCNN2KCNN3KMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222262-B2 | Indazolyl derivatives useful as potassium channel modulating agents | NEUROSEARCH A/S (DK) | 2012-07-17 | — | — | US | claimed |
| US-20090325989-A1 | INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2009-12-31 | — | — | US | claimed |
| US-8222262-B2 | Indazolyl derivatives useful as potassium channel modulating agents | NEUROSEARCH A/S (DK) | 2012-07-17 | — | — | US | disclosed |
| US-20090325989-A1 | INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2009-12-31 | — | — | US | disclosed |
| EP-2074113-A1 | INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NeuroSearch A/S (DK) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008040753-A1 | INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325989-A1 | INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | KCND2, KCNN3, KCNJ2 | KCNN2 8/4885KCNN3 2/4885KMT2A 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.